Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain, the CRIVERVA study

  • Trapero Bertrán, Marta
  • Acera Pérez, Amelia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Manresa, J. M|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchís, Mireia
The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women. ClinicalTrials.gov Identifier: . The online version of this article (doi:10.1186/s12889-017-4115-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increasing Cervical Cancer Screening Coverage: A randomised, Community-Based Clinical Trial

  • Acera Pérez, Amelia
  • Manresa, J.M.|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Trapero Bertrán, Marta
  • Hidalgo Valls, Pablo Andres
  • Sánchez Sánchez, Norman
  • De Sanjose, Silvia|||0000-0002-5909-676X
Background. Opportunistic cervical cancer screening can lead to suboptimal screening coverage. Coverage could be increased after a personalised invitation to the target population. We present a community randomized intervention study with three strategies aiming to increase screening coverage.Methods. The CRICERVA study is a community-based clinical trial to improve coverage of population based screening in the Cerdanyola SAP area in Barcelona.A total of 32,858 women residing in the study area, aged 30 to 70 years were evaluated. A total of 15,965 women were identified as having no registration of a cervical cytology in the last 3.5 years within the Public Health data base system. Eligible women were assigned to one of four community randomized intervention groups (IGs): (1) (IG1 N = 4197) personalised invitation letter, (2) (IG2 N., Conclusions. The study confirms that using individual contact methods and assigning a fixed screening date notably increases participation in screening. The response to the invitation is strongly dependent on age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Consumption of ultra-processed food and drinks and chronic lymphocytic leukemia in the mcc-spain study

  • Solans, Marta|||0000-0002-2397-0435
  • Fernández-Barrés, Sílvia|||0000-0002-9977-2291
  • Romaguera, Dora|||0000-0002-5762-8558
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Gracia-Lavedan, Esther
  • Costas, Laura
  • Robles, Claudia
  • González Barca, Eva|||0000-0002-1323-1508
  • Banda, Esmeralda de la
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias|||0000-0001-9850-9793
  • Llorca, Javier|||0000-0001-8569-861X
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • Gimeno, Eva|||0000-0002-3534-6189
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Sanjose, Sílvia de
  • Amiano, Pilar
  • Casabonne, Delphine
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest that lifestyle and environmental factors such as diet might play a role in the development of CLL. Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study) including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based controls were used. The usual diet during the previous year was collected through a validated food frequency questionnaire and food and drink consumption was categorized using the NOVA classification scheme. Logistic regression models adjusted for potential confounders were used. Overall, no association was reported between the consumption of UPF and CLL cases (OR per each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94; 1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed, chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident cases merit further research, ideally in well-powered studies with a prospective design.